ArticleBMJ open2024

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.

James Blackstone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.